Compare FND & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FND | DNTH |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.5B |
| IPO Year | 2014 | 2018 |
| Metric | FND | DNTH |
|---|---|---|
| Price | $56.21 | $99.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $73.44 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.05 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,684,088,000.00 | $2,036,000.00 |
| Revenue This Year | $7.53 | N/A |
| Revenue Next Year | $7.68 | $29.48 |
| P/E Ratio | $151.85 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $42.64 | $18.08 |
| 52 Week High | $92.41 | $102.37 |
| Indicator | FND | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 61.44 |
| Support Level | $53.94 | $79.27 |
| Resistance Level | $56.49 | N/A |
| Average True Range (ATR) | 2.20 | 5.39 |
| MACD | -0.34 | 0.67 |
| Stochastic Oscillator | 47.16 | 82.57 |
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.